-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 6th, the National Medical Security Bureau announced the "List of Drugs That Passed the Preliminary Form Review for the Adjustment of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue in 2022", and 344 drugs passed the preliminary form review
.
.
Zhongxin Jingwei noted that in the list of drugs that passed the formal examination, including the broad-spectrum targeted drug ralotinib sulfate developed by Bayer Pharmaceuticals? Sacs and ralotinib sulfate oral solutions, according to the drug label, are indicated by well-validated tests that are diagnosed as patients carrying the neurotrophic tyrosine receptor kinase (NTRK) fusion gene and excluding known acquired resistance mutations, patients with locally advanced, metastatic disease, or surgical resection that may lead to serious complications, and patients
without satisfactory alternative therapy or previous treatment failures.
without satisfactory alternative therapy or previous treatment failures.
From the perspective of the reason for the choice, the National Medical Insurance Bureau said that lalotinib is the first drug approved for marketing in the world and China, with unlimited tumor species and accurate targeting of NTRK gene fusion, and there is no reference product in the current catalog, and there is no reference product in
China.
China.
According to public information, lalotinib sulfate was first approved for marketing
in the United States on November 26, 2018.
In April 2022, lalotinib sulfate capsules were officially listed
with the approval of the State Drug Administration of China.
It is worth noting that according to public information, the oral capsules of ralotinib sulfate are priced relatively high in the United States, at 32,800 US dollars per month, which is 228,900 yuan at the current exchange rate, and the annual fee is calculated as 393,600 US dollars per year, or 2,746,300 yuan
.
in the United States on November 26, 2018.
In April 2022, lalotinib sulfate capsules were officially listed
with the approval of the State Drug Administration of China.
It is worth noting that according to public information, the oral capsules of ralotinib sulfate are priced relatively high in the United States, at 32,800 US dollars per month, which is 228,900 yuan at the current exchange rate, and the annual fee is calculated as 393,600 US dollars per year, or 2,746,300 yuan
.
In addition to the lalotinib sulfate capsules, Zhongxin Jingwei noted that WuXi Junonuo's CAR-T product Requiolensae Injection is also on the
list.
It is used to treat relapsed or refractory large B-cell lymphoma in adults after second-line or higher systemic therapy
.
list.
It is used to treat relapsed or refractory large B-cell lymphoma in adults after second-line or higher systemic therapy
.
Previously, the pricing of Ricky Olonsay injection was also relatively high
.
On December 29, 2021, the Liaoning Provincial Centralized Procurement Network for Drugs and Medical Consumables announced and implemented the results of the direct network procurement of innovative drugs, and the price of Wujie Juno's Ricky Olonsai Injection was 1.
29 million yuan per piece, with a volume of about 5 ml per stick, containing no less than 25 *10^6CAR-T cells
.
.
On December 29, 2021, the Liaoning Provincial Centralized Procurement Network for Drugs and Medical Consumables announced and implemented the results of the direct network procurement of innovative drugs, and the price of Wujie Juno's Ricky Olonsai Injection was 1.
29 million yuan per piece, with a volume of about 5 ml per stick, containing no less than 25 *10^6CAR-T cells
.
Regarding the significance of the preliminary formal examination, the National Medical Insurance Bureau explained that the preliminary formal examination is a preliminary review of whether the declared drugs meet the declaration conditions for the adjustment of the national medical insurance drug catalogue in that year and the integrity of the drug information
.
The preliminary formal review of the drug declaration materials can ensure that the declared drugs meet the declaration conditions on the one hand, and on the other hand, the completeness and standardization of the declaration materials are reviewed
.
.
The preliminary formal review of the drug declaration materials can ensure that the declared drugs meet the declaration conditions on the one hand, and on the other hand, the completeness and standardization of the declaration materials are reviewed
.
As for the inclusion of high-priced drugs in the formal examination, the National Medical Insurance Bureau said that this year, some of the more expensive drugs passed the preliminary formal examination, which only meant that the drug met the declaration conditions and obtained the qualification to
enter the next link.
Whether such drugs can eventually enter the national medical insurance drug list also needs to be strictly evaluated in many ways, including economy, and the exclusive drugs that pass the review must be negotiated, and the non-exclusive drugs must be bid, and only after negotiation or bidding can they be included in the list
.
enter the next link.
Whether such drugs can eventually enter the national medical insurance drug list also needs to be strictly evaluated in many ways, including economy, and the exclusive drugs that pass the review must be negotiated, and the non-exclusive drugs must be bid, and only after negotiation or bidding can they be included in the list
.
On the 6th, the National Medical Security Bureau announced the "List of Drugs That Passed the Preliminary Form Review for the Adjustment of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue in 2022", and 344 drugs passed the preliminary form review
.
.
Zhongxin Jingwei noted that in the list of drugs that passed the formal examination, including the broad-spectrum targeted drug ralotinib sulfate developed by Bayer Pharmaceuticals? Sacs and ralotinib sulfate oral solutions, according to the drug label, are indicated by well-validated tests that are diagnosed as patients carrying the neurotrophic tyrosine receptor kinase (NTRK) fusion gene and excluding known acquired resistance mutations, patients with locally advanced, metastatic disease, or surgical resection that may lead to serious complications, and patients
without satisfactory alternative therapy or previous treatment failures.
Drugs Drugs Diseaseswithout satisfactory alternative therapy or previous treatment failures.
From the perspective of the reason for the choice, the National Medical Insurance Bureau said that lalotinib is the first drug approved for marketing in the world and China, with unlimited tumor species and accurate targeting of NTRK gene fusion, and there is no reference product in the current catalog, and there is no reference product in
China.
China.
According to public information, lalotinib sulfate was first approved for marketing
in the United States on November 26, 2018.
In April 2022, lalotinib sulfate capsules were officially listed
with the approval of the State Drug Administration of China.
It is worth noting that according to public information, the oral capsules of ralotinib sulfate are priced relatively high in the United States, at 32,800 US dollars per month, which is 228,900 yuan at the current exchange rate, and the annual fee is calculated as 393,600 US dollars per year, or 2,746,300 yuan
.
in the United States on November 26, 2018.
In April 2022, lalotinib sulfate capsules were officially listed
with the approval of the State Drug Administration of China.
It is worth noting that according to public information, the oral capsules of ralotinib sulfate are priced relatively high in the United States, at 32,800 US dollars per month, which is 228,900 yuan at the current exchange rate, and the annual fee is calculated as 393,600 US dollars per year, or 2,746,300 yuan
.
In addition to the lalotinib sulfate capsules, Zhongxin Jingwei noted that WuXi Junonuo's CAR-T product Requiolensae Injection is also on the
list.
It is used to treat relapsed or refractory large B-cell lymphoma in adults after second-line or higher systemic therapy
.
list.
It is used to treat relapsed or refractory large B-cell lymphoma in adults after second-line or higher systemic therapy
.
Previously, the pricing of Ricky Olonsay injection was also relatively high
.
On December 29, 2021, the Liaoning Provincial Centralized Procurement Network for Drugs and Medical Consumables announced and implemented the results of the direct network procurement of innovative drugs, and the price of Wujie Juno's Ricky Olonsai Injection was 1.
29 million yuan per piece, with a volume of about 5 ml per stick, containing no less than 25 *10^6CAR-T cells
.
Procurement Procurement.
On December 29, 2021, the Liaoning Provincial Centralized Procurement Network for Drugs and Medical Consumables announced and implemented the results of the direct network procurement of innovative drugs, and the price of Wujie Juno's Ricky Olonsai Injection was 1.
29 million yuan per piece, with a volume of about 5 ml per stick, containing no less than 25 *10^6CAR-T cells
.
Regarding the significance of the preliminary formal examination, the National Medical Insurance Bureau explained that the preliminary formal examination is a preliminary review of whether the declared drugs meet the declaration conditions for the adjustment of the national medical insurance drug catalogue in that year and the integrity of the drug information
.
The preliminary formal review of the drug declaration materials can ensure that the declared drugs meet the declaration conditions on the one hand, and on the other hand, the completeness and standardization of the declaration materials are reviewed
.
.
The preliminary formal review of the drug declaration materials can ensure that the declared drugs meet the declaration conditions on the one hand, and on the other hand, the completeness and standardization of the declaration materials are reviewed
.
As for the inclusion of high-priced drugs in the formal examination, the National Medical Insurance Bureau said that this year, some of the more expensive drugs passed the preliminary formal examination, which only meant that the drug met the declaration conditions and obtained the qualification to
enter the next link.
Whether such drugs can eventually enter the national medical insurance drug list also needs to be strictly evaluated in many ways, including economy, and the exclusive drugs that pass the review must be negotiated, and the non-exclusive drugs must be bid, and only after negotiation or bidding can they be included in the list
.
enter the next link.
Whether such drugs can eventually enter the national medical insurance drug list also needs to be strictly evaluated in many ways, including economy, and the exclusive drugs that pass the review must be negotiated, and the non-exclusive drugs must be bid, and only after negotiation or bidding can they be included in the list
.
